Iovance Biotherapeutics, Inc. Common Stock
Here’s whether Iovance Biotherapeutics, Inc. Common Stock (IOVA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.74% over 10 days); RSI 65 — healthy momentum range; strong 1-year return of +135.0%. Concerns: 3-month momentum negative (-21.8%). Currently 24.9% off its 52-week high. Score: +5/7.
IOVA is in a confirmed uptrend, trading above both its 50-day ($3.69) and 200-day ($2.90) moving averages. An RSI of 64.7 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +135.0% compares to +24.4% for SPY (beat the market by 110.6%). The current 24.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.